Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Richard N Rosenthal & Viral V Goradia. (2017) Advances in the delivery of buprenorphine for opioid dependence. Drug Design, Development and Therapy 11, pages 2493-2505.
Read now
Read now
Icro Maremmani, Benjamin Rolland, Lorenzo Somaini, Carlos Roncero, Jens Reimer, Nat Wright, Richard Littlewood, Peter Krajci, Hannu Alho, Oscar D’Agnone & Nicolas Simon. (2016) Buprenorphine dosing choices in specific populations: review of expert opinion. Expert Opinion on Pharmacotherapy 17:13, pages 1727-1731.
Read now
Read now
Edward V. Nunes. (2011) The Design and Analysis of Multisite Effectiveness Trials: A Decade of Progress in the National Drug Abuse Clinical Trials Network. The American Journal of Drug and Alcohol Abuse 37:5, pages 269-272.
Read now
Read now
Articles from other publishers (22)
Mark K. Greenwald, Katharina L. Wiest, Barbara R. Haight, Celine M. Laffont & Yue Zhao. (2023) Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder. Harm Reduction Journal 20:1.
Crossref
Crossref
Joanne Huang, Heba Edrees & Grace Lee. (2023) A Case Series on Serotonin Syndrome from Concomitant use of linezolid With Methadone, Buprenorphine, and/or Dextroamphetamine. Journal of Pharmacy Practice, pages 089719002311827.
Crossref
Crossref
Hesham Farouk Elarabi, Amanda J. Lee, Abdu Adem, Abuelgasim Elrasheed, John Marsden & Hamad Al Ghaferi. (2022) Lower buprenorphine elimination rate constant is associated with lower opioid use. Psychopharmacology 239:10, pages 3213-3221.
Crossref
Crossref
Olivia K. Golan, Rachel Totaram, Elizabeth Perry, Kennicia Fortson, Raul Rivera-Atilano, Rebecca Entress, Matthew Golan, Barbara Andraka-Christou, Daniel Whitaker & Therese Pigott. (2022) Systematic review and meta-analysis of changes in quality of life following initiation of buprenorphine for opioid use disorder. Drug and Alcohol Dependence 235, pages 109445.
Crossref
Crossref
Sarah M. Allen, Taylor A. Nichols, Janet Fawcett & Show Lin. (2022) Outcomes associated with once‐daily versus multiple‐daily dosing of buprenorphine/naloxone for opioid use disorder. The American Journal on Addictions 31:3, pages 173-179.
Crossref
Crossref
Michael H. Baca-Atlas & Joseph B. Williams. (2021) Treatment of Opioid Use Disorder Attributed to Fentanyl With High-Dose Buprenorphine. Journal of Clinical Psychopharmacology 41:1, pages 83-85.
Crossref
Crossref
Jillian L. Kyzer & Cody J. Wenthur. (2020) Classics in Chemical Neuroscience: Buprenorphine. ACS Chemical Neuroscience 11:10, pages 1385-1399.
Crossref
Crossref
Katie J. Binger, Elayne D. Ansara, Talia M. Miles & Samantha L. Schulte. (2020) Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder. Mental Health Clinician 10:3, pages 80-84.
Crossref
Crossref
Anne C. Andorn, Barbara R. Haight, Sunita Shinde, Paul J. Fudala, Yue Zhao, Christian Heidbreder, Susan M. Learned, Norma Lynn Fox, Vijay R. Nadipelli, David Hassman & Daniel Rutrick. (2020) Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis. Journal of Clinical Psychopharmacology 40:3, pages 231-239.
Crossref
Crossref
Randi Sokol, Mark Albanese, Aaronson Chew, Jessica Early, Ellie Grossman, David Roll, Greg Sawin, Dominic J. Wu & Zev Schuman-Olivier. (2019) Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation. Addiction Science & Clinical Practice 14:1.
Crossref
Crossref
Hesham Elarabi, Abuelgasim Elrasheed, Ahmed Ali, Mansour Shawky, Nael Hasan, Tarek A. Gawad, Abdu Adem & John Marsden. (2019) Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management. Journal of Addiction 2019, pages 1-11.
Crossref
Crossref
Saul Alcaraz, Francisco González-Saiz, Joan Trujols, Esperanza Vergara-Moragues, Núria Siñol & José Pérez de los Cobos. (2018) A cluster-analytic profiling of heroin-dependent patients based on level, clinical adequacy, and patient-desired adjustment of buprenorphine dosage during buprenorphine-naloxone maintenance treatment in sixteen Spanish centers. Drug and Alcohol Dependence 187, pages 278-284.
Crossref
Crossref
Francisco González-Saiz, Oscar Lozano Rojas, Joan Trujols, Saul Alcaraz, Núria Siñol & José Pérez de los Cobos. (2018) Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. Drug and Alcohol Dependence 183, pages 127-133.
Crossref
Crossref
Anthony J. Accurso, Joshua D. Lee & Jennifer McNeely. (2017) High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio. Journal of Substance Abuse Treatment 83, pages 62-67.
Crossref
Crossref
Suzanne Nielsen, Raimondo Bruno, Louisa Degenhardt, Apo Demirkol & Nicholas Lintzeris. (2017) Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. Drug and Alcohol Review 36:3, pages 311-316.
Crossref
Crossref
Linda Gowing, Robert Ali, Jason M White & Dalitso Mbewe. (2017) Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews 2017:2.
Crossref
Crossref
Anthony J. Accurso & Darius A. Rastegar. (2016) The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence. Journal of Substance Abuse Treatment 61, pages 74-79.
Crossref
Crossref
Suzanne Nielsen, Raimondo Bruno, Bridin Murnion, Adrian Dunlop, Louisa Degenhardt, Apo Demirkol, Peter Muhleisen & Nicholas Lintzeris. (2016) Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. Drug and Alcohol Review 35:1, pages 70-75.
Crossref
Crossref
Brandon S. Bentzley, Kelly S. Barth, Sudie E. Back & Sarah W. Book. (2015) Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes. Journal of Substance Abuse Treatment 52, pages 48-57.
Crossref
Crossref
Mark K. Greenwald, Sandra D. Comer & David A. Fiellin. (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug and Alcohol Dependence 144, pages 1-11.
Crossref
Crossref
Paolo Mannelli, Li-Tzy Wu, Kathleen S. Peindl, Marvin S. Swartz & George E. Woody. (2014) Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: A very low dose naltrexone and buprenorphine open label trial. Drug and Alcohol Dependence 138, pages 83-88.
Crossref
Crossref
Michael Ferri, Alistair J. Reid Finlayson, Li Wang & Peter R. Martin. (2014) Predictive Factors for Relapse in Patients on Buprenorphine Maintenance. The American Journal on Addictions 23:1, pages 62-67.
Crossref
Crossref